Cyclodextrins in nasal drug delivery

Merkus, F. W. H. M.; Verhoef, J.; Marttin, E.; Romeijn, S.G.; Kuy, Hugo van der; Hermens, W. A. J. J.; Schipper, Nicolaas

doi:10.1016/s0169-409x(98)00054-4

Cited by 193 publications

(73 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suggests a passive diffusion of the CDs into the lipid bilayer by directing their opened secondary rim towards the lipidic polar groups while remaining anchored to the glycerol-ester groups and phosphate by hydrogen bond formation. In barrier-forming epithelial cells, the effect of CDs has been evaluated in vitro and in vivo in the dermis, in the nasal cavities and in the gut where it promotes drug absorption across these barriers as a result of their cell membrane cholesterol extraction [20,[31][32][33]. At the neurovascular endothelial level, the action of CDs toward the BBB endothelium has been studied by Monnaert et al (2004 [34]) on an in vitro model of the bovine BBB where they described that α-CD removes phospholipids, β-CD extracts phospholipids and cholesterol whereas γ-CD is less lipid-selective than other CDs.…”

Section: Direct Action Of the Cds On Cell Membranesmentioning

confidence: 99%

“…Phospholipids, acting as acetylcholine precursor, would counteract the loss of cholinergic neurons responsible for impaired cognition in AD patients. The chitosan/phospholipid/β-CD microspheres were tested in vivo in rats modeling AD following Aβ [25][26][27][28][29][30][31][32][33][34][35] injection into the hippocampus. In these animals, learning and memory were improved according to Morris water maze test data compared to untreated littermates.…”

Section: Alzheimer's Diseasementioning

confidence: 99%

See 1 more Smart Citation

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

et al. 2016

View full text Add to dashboard Cite

Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE ® CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer's, Parkinson's and Huntington's diseases are currently on-going.

show abstract

Section: Direct Action Of the Cds On Cell Membranesmentioning

confidence: 99%

Section: Alzheimer's Diseasementioning

confidence: 99%

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Me-β-CDs were primarily found to be beneficial excipients on nasal drug delivery systems. [140][141][142][143][144][145] …”

Section: Cyclodextrins and Nanotechnologymentioning

confidence: 99%

Untitled

Budhwar¹

2018

AJP

View full text Add to dashboard Cite

Inclusion complexes have various applications in different fields of drug delivery and pharmaceutical industry due to their ability of complexation with guest molecules and enhancement of the physicochemical properties of guest molecules. Cyclodextrins and their derivatives have the ability to encapsulate the bioactive compounds into its cavity and protect these from the environmental conditions, improve the solubility, bioavailability, and other properties also. The aim of this review is to highlight the advantages of cyclodextrins in the enhancement of physicochemical properties of drugs (such as solubility, stability, bioavailability, permeability, and others), different methods for production and various characterization techniques used for evaluation of complexes. Applications of cyclodextrin complexes in pharmaceutical and other fields are also explained here with examples. Thus cyclodextrins, because of their continuing ability to find several novel applications in drug delivery, are expected to solve many problems accompanied with the delivery of different novel drugs through various delivery routes.

show abstract

“…The selection of the excipients primarily based on the requirements of the particular dosage form. Gelling agents, viscosity enhancers, solubilizers, buffer components, antioxidants, preservatives, humectants and flavoring agents or taste masking agents are an assortment of the common excipients (Merkus et al, 1991a;Merkus et al, 1999a;Davis & Illum, 2003). The excipients selected for a formulation required to be compatible and not to hamper the absorption of drug from nasal mucosal surface.…”

Section: Pharmaceutical Excipientsmentioning

confidence: 99%

Nasal-nanotechnology: revolution for efficient therapeutics delivery

2014

View full text Add to dashboard Cite

Context: In recent years, nanotechnology-based delivery systems have gained interest to overcome the problems of restricted absorption of therapeutic agents from the nasal cavity, depending upon the physicochemical properties of the drug and physiological properties of the human nose. Objective: The well-tolerated and non-invasive nasal drug delivery when combined with the nanotechnology-based novel formulations and carriers, opens the way for the effective systemic and brain targeting delivery of various therapeutic agents. To accomplish competent drug delivery, it is imperative to recognize the interactions among the nanomaterials and the nasal biological environment, targeting cell-surface receptors, drug release, multiple drug administration, stability of therapeutic agents and molecular mechanisms of cell signaling involved in patho-biology of the disease under consideration. Methods: Quite a few systems have been successfully formulated using nanomaterials for intranasal (IN) delivery. Carbon nanotubes (CNTs), chitosan, polylactic-co-glycolic acid (PLGA) and PLGA-based nanosystems have also been studied in vitro and in vivo for the delivery of several therapeutic agents which shown promising concentrations in the brain after nasal administration. Results and conclusion: The use of nanomaterials including peptide-based nanotubes and nanogels (NGs) for vaccine delivery via nasal route is a new approach to control the disease progression. In this review, the recent developments in nanotechnology utilized for nasal drug delivery have been discussed.

show abstract

Cyclodextrins in nasal drug delivery

Cited by 193 publications

References 65 publications

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Untitled

Nasal-nanotechnology: revolution for efficient therapeutics delivery

Contact Info

Product

Resources

About